Sana Biotechnology Inc (SANA) FinancialsSANASana Biotechnology Inc

Evaluating the bottom line, Sana Biotechnology, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -152.87%, provide a clear picture of how effectively SANA converts its operational activities into shareholder value.

In the context of the broader market, SANA competes directly with industry leaders such as IVA and DSGN. With a market capitalization of $740.92M, it holds a leading position in the sector. When comparing efficiency, SANA's gross margin of N/A stands against IVA's 100.00% and DSGN's N/A. Such benchmarking helps identify whether Sana Biotechnology, Inc. is trading at a premium or discount relative to its financial performance.

Sana has consistently reported negative net income, with losses increasing to -$63,635,000 in Q2 2026. The forward P/E ratio is 0, indicating no earnings expected in the near future, and the price-to-book ratio is high at 4.79, suggesting overvaluation relative to its equity.